Tim-3 expression in glioma cells is associated with drug resistance
Loading...
Date
2019-08
Journal Title
Journal ISSN
Volume Title
Publisher
Wolters Kluwer India Pvt. Ltd.
Abstract
Objective: T-cell immunoglobulin and mucin-domain containing-3 (Tim-3) has been widely recognized as a negative regulator of antitumor immunity. However, the mechanism by which Tim-3 suppresses antitumor treatment in gliomas remains unclear. This study aims to explore whether Tim-3 is expressed and to evaluate its effect in drug-fasted glioma cells. Subjects and Methods: U87 and U251 glioma cell lines were tested. Cell proliferation activity, cell viability, and the protein and mRNA levels of Tim-3 were detected using CCK-8, flow cytometry, Western blotting, and reverse transcription-quantitative polymerase chain reaction, respectively. Enhancement of the sensitivity of glioma cells to chemotherapeutic agents was tested after inhibiting Tim-3 expression using Tim-3 small interfering RNAs (siRNA). Results: As temozolomide (TMZ) concentration increased, the ratio of apoptotic cells also increased accordingly. However, the level of Tim-3 expression in living cells from the high-dose group was higher than in the low- and middle-dose groups. After interfering with the expression of Tim-3 using siRNA against Tim-3, the killing effect of TMZ rose through an increase in apoptosis. Conclusions: The presence of Tim-3 mRNA and protein in glioma cells was detected. Significantly, knocking down Tim-3 expression improved the potential of TMZ treatment.
Description
Keywords
Citation
Ji Zhang, Zheng Quan Zhu, Yan Xia Li, Qiu Feng Zhuang, Lai Yuanhong, Li Shao Fang, Xu Xiao Bing, Liu Jian Min. Tim-3 expression in glioma cells is associated with drug resistance. Journal of Cancer Research and Therapeutics. 2019 Aug; 15(4): 882-888